Orasure Technologies opened lower at $3.52, compared with its previous close of $3.56. In the last trading session, the stock traded between $3.40 and $3.67. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Orasure Technologies is now worth
$ 36.89
Resulting in a loss of
$ 63.11 (63.11%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.06 (+1.54%)
Day High
$3.67
Day Low
$3.40
Day Open
$3.52
Prev Close
$3.56
Volume
5,14,134
1W Return
-2.74%
1M Return
-8.11%
3M Return
-6.95%
6M Return
19.70%
1Y Return
46.95%
Fundamentals
Market Cap ($ Mn)
250
PE Ratio
-
PB Ratio
0.78
PEG Ratio
-
ROE
-18.18%
ROCE
-15.93%
EPS (TTM)
$-0.19
Investment Returns
1 Week
-2.74%
1 Month
-8.11%
3 Months
-6.95%
6 Months
19.70%
9 Months
28.19%
Financials
Quarterly
All values in $ Mn
27.1
Sep 25
26.8
Dec 25
27.9
Mar 26
0.0
Mar 26
30.6
Jun 26
30.9
Sep 26
Updates
10Nov
OraSure Technologies Q3FY26 Results: Revenue up 14% to $30.9m, margins expand
Q3FY26 revenue rose 14% YoY to $30.9 million, driven by diagnostic and SMS segments. GAAP gross margin expanded 173 bps to 45.2% due to operational efficiencies. FY26 sales guidance of $120.427 million remains below consensus estimate of $121.304 million. FDA EUA granted for OraQuick Ebola 2.0 test; initial commercial orders fulfilled. Cash flow from operations break-even target pushed to second half of 2027.
3 days ago
6Aug
OraSure Technologies Q3 Results: Sales guidance range set at $29.5M-$32.5M
OraSure Technologies guides Q3 sales to $29.500M-$32.500M, bracketing the $31.143M analyst estimate. The wide range implies potential for both a miss and a beat, with the lower bound representing a ~5.3% shortfall against consensus.
3mo ago
23Jul
OraSure to announce Q2 2026 financial results on August 5
OraSure Technologies, Inc. is set to announce its Q2 2026 financial results on August 5, 2026, followed by an earnings call at 5 p.m. ET. The webcast will be available on the company’s website and archived for one year. OraSure specializes in rapid diagnostic tests and sample collection solutions.
3mo ago
22Jul
OraQuick Ebola 2.0 secures FDA EUA for rapid detection
OraSure Technologies, Inc. secured FDA Emergency Use Authorization for its OraQuick Ebola 2.0 Rapid Antigen Test, designed to detect Bundibugyo, Zaire, Sudan, and Taï Forest viruses. The test provides results in 30 minutes without instruments and is vital for the ongoing outbreak in Central Africa. OraSure is increasing production to address the public health emergency declared by the WHO.
